Biotest AG / Key word(s): Corporate Action 17.03.2015 15:45 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- / Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital increase without issuing new shares - Proposed share split with the relation of one to three Dreieich, 17 March 2015. Biotest AG will propose a capital increase from capital funds and a share split with the relation of one to three by means of a reclassification of the share capital to its Annual General Meeting on 7 May 2015. Biotest share prices have increased significantly in recent years. The proposed share split is intended to promote the liquidity and accessibility of the Biotest shares and to make the Biotest shares even more attractive also for a broader group of investors. The share capital of Biotest AG currently amounts to EUR 33,767,639.04 and is divided into 6,595,242 ordinary shares and into 6,595,242 preference shares without voting rights. Thus, one ordinary or preference share has a proportional amount of the share capital of EUR 2.56. After the implementation of the capital increase from capital funds by EUR 5,803,812.96 to EUR 39,571,452.00 without issuing new shares and the share split, each current holder of one existing ordinary or preference share would hold in future three ordinary or preference shares with a proportional amount of the share capital of EUR 1.00. The agenda of the Annual General Meeting resolved today by the Supervisory Board and the Management Board will be published presumably on 25 March 2015. In accordance with the proposed share split, Biotest also proposed several amendments to the articles of association, e.g. appropriation of profit and the remuneration of the Supervisory Board. Biotest Aktiengesellschaft Board of Management Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2,100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart 17.03.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG LandsteinerstraÃe 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Biotest AG: Biotest proposes
Top 10 Most Recent News Articles
BON’s Oat Lab Bet Puts Scale and Standards in Focus
Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...
Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus
A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...
Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions
One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...
Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives
When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...
Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus
A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....
Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach
Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...
Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers
Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...
Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern
Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...
Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors
An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...
Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk
A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...
Continue ReadingTop 5 Most Recently Viewed Articles
Bitfarms and Riot Platforms Reach Important Settlement Agreement
Bitfarms Ltd and Riot Platforms Reach Settlement on Disputes Today, Bitfarms Ltd (NASDAQ:BITF), a leading player in the cryptocurrency mining field, announced that it has successfully settled disputes with Riot Platforms (NASDAQ:RIOT). This important settlement seeks to resolve various conflicts that existed between the two companies, although the specific details of...
Continue Reading
Peer To Peer Network Unveils Strategic Insights for PTOP Labs
Peer To Peer Network Reveals Insights on PTOP Intelligence Labs Peer To Peer Network (OTC: PTOP) has taken a decisive step towards revolutionizing investor communication and engagement with the introduction of PTOP Intelligence Labs. During a recent call, the company’s newly appointed division president, Derek McCarthy, shared insights into the innovative AI-driven...
Continue Reading
Firsthand Technology Fund Reports Third Quarter Financial Performance
Firsthand Technology Value Fund Financial Overview Firsthand Technology Value Fund, Inc. (OTCQB: SVVC), a publicly trading venture capital fund focused on technology and cleantech investments, has provided an update on its financial performance for the recent quarter. As of the end of September, the Fund reported net assets amounting to $296,547, translating to $0.04 per...
Continue Reading
Nanit Unveils Innovative AI Sleep Score Tailored for Babies
Nanit Launches Groundbreaking AI Sleep Score for Infants Nanit has introduced an innovative Sleep Score feature aimed specifically at helping parents enhance their babies' sleep quality. This groundbreaking technology translates complex clinical-grade sleep data into a single, easy-to-understand number. Parents will now have access to a powerful tool that demystifies...
Continue Reading
The Surge of the Manufacturing Execution System Market
Introduction to the Manufacturing Execution System Market The global manufacturing execution system (MES) market is experiencing remarkable growth, fueled by the rising trend of digital transformation across various manufacturing sectors. As industries evolve, the demand for real-time data and efficient management of production processes is becoming increasingly critical....
Continue Reading